BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Sanguine Corporation (SGNC) Announces Significant PHER-O2 Order From Virginia Commonwealth University


7/27/2010 9:43:47 AM

PASADENA, CA--(Marketwire - July 27, 2010) - Sanguine Corporation (OTCBB: SGUI), a bio-pharmaceutical company developing products for use in biomedical and medical device applications, announces that the Company has recently received a significant order from Virginia Commonwealth University (VCU) for PHER-O2, the Company's ultra-oxygen carrying perfluorocarbon-based product. The University is considered to be one of the foremost research institutions in the United States with groundbreaking work using perfluorocarbons (PFCs). The researchers at the VCU Reanimation Engineering Shock Center (VCURES) are conducting a number of very promising pre-clinical trials, including: Neurological Events (Traumatic Brain Injury (TBI), Traumatic Spinal Cord Injury, Stroke), Organ Preservation (Cardioplegia, Heart Transplant, Liver Preservation, Kidney Transplant, Islet Cell Preservation), and Intravenous Enhanced Oxygen Delivery (Multifunctional Resuscitation Solutions, Sickle Cell Crisis, Carbon Monoxide Poisoning, Cardiopulmonary Resuscitation).

The University contracts are part of several US Federal Government funded projects underway. The University contracts amount to many millions of dollars in overall project funding. Additional projects are in various phases of the grant funding process. Sanguine will be acting as the sole supplier to these projects and will seek to participate as a partner at some point in the near future.

Mr. Frank Marra, a Company spokesperson, stated, "As a result of our approach, begun last year, to accelerate our growth through strategic and targeted development alliances, we are extremely excited about our relationship with VCU. Under Dr. Bruce Spiess' leadership, VCURES' team is considered to be at the forefront of the world's experts in research and development of innovative and novel pefluorocarbon-based solutions to a number of critical diseases and injuries. The research to be conducted with the PHER-O2 is expected to significantly advance the market acceptance of PFCs and lead to many important products and treatment methods for critical diseases and injuries."

For information related to the Sanguine Corporation, contact Investor Relations: Michael Dancy, 801-746-3570, email: medancy@dancycorp.com.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.


Michael Dancy
801-746-3570
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES